Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
Rhea-AI Summary
Sensei Biotherapeutics (NASDAQ: SNSE) has announced an upcoming presentation of clinical data at the ESMO Congress 2025 in Berlin, Germany. The presentation will focus on results from the Phase 1 dose expansion cohort studying solnerstotug, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® (cemiplimab).
The study specifically examines patients with advanced solid tumors resistant to prior PD-(L)1 therapy. Dr. Kyriakos Papadopoulos from START, San Antonio will present the findings on October 17, 2025 during a mini oral session.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SNSE gained 7.50%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.4% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $695K to the company's valuation, bringing the market cap to $10M at that time. Trading volume was very high at 3.6x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany.
Presentation Details:
Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD-(L)1 therapy
Presenter: Dr. Kyriakos Papadopoulos, Co-Director of Clinical Research at START, San Antonio
Abstract Number: 3933
Presentation Date & Time: Friday, October 17, 2025 from 2:00 – 3:30 CEST
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor & Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When will Sensei Biotherapeutics (SNSE) present its solnerstotug clinical data at ESMO 2025?
What is the focus of Sensei Biotherapeutics' (SNSE) Phase 1 clinical trial presentation?
Who will present Sensei Biotherapeutics' (SNSE) clinical trial results at ESMO 2025?
What type of cancer treatment is Sensei Biotherapeutics (SNSE) developing?
